ANI Pharmaceuticals (ANIP) lifts 2026 revenue forecast as Cortrophin Gel momentum drives Q1 results

Key takeaways

• Ticker: ANIP
• Revenue: $237.5 million in Q1 2026, up 20.5% year over year
• GAAP net income: $29.5 million; GAAP EPS of $1.28
• Adjusted non-GAAP earnings: EBITDA of $63.0 million; adjusted EPS of $2.05
• Rare Disease focus: Cortrophin Gel net revenues of $75.1 million, up 42.1% YoY
• Guidance raised: 2026 total net revenue forecast $1.08–$1.14 billion; Cortrophin Gel net revenue forecast $540–$575 million; adjusted non-GAAP diluted EPS $9.19–$9.69; adjusted EBITDA $285–$300 million
• Share repurchase: $100 million authorized by the Board
• Analyst context: The filing does not disclose EPS consensus or explicit expectations for a potential earnings surprise; management’s tone implies confidence in the mid- to high-teens growth trajectory for core franchises.

Executive snapshot

ANI’s leadership framed the quarter as evidence of solid execution across the business, with Cortrophin Gel and related Rare Disease initiatives delivering meaningful top-line contributions. CEO Nikhil Lalwani emphasized momentum in Cortrophin Gel and progress on expanding the Rare Disease sales force, particularly in neurology, rheumatology, and nephrology, while noting insurance re-verifications contributed to seasonal variability in the first half of the quarter.

On the guidance lift, Lalwani highlighted the company’s profitability trajectory and its commitment to advancing Cortrophin Gel’s opportunities in acute gouty arthritis flares, alongside continued strength in the Generics business and Rare Disease portfolio. The lift in revenue guidance aligns with expectations for continued demand in core assets and the strategic expansion of commercial coverage.

Numbers at a glance

The press release provides a constellation of metrics that map to the company’s strategic bets:

• Q1 2026 net revenues: $237.5 million (+20.5% YoY)
• Cortrophin Gel net revenues: $75.1 million for the quarter, +42.1% YoY
• GAAP net income available to common shareholders: $29.5 million
• GAAP earnings per share: $1.28
• Adjusted non-GAAP EBITDA: $63.0 million
• Adjusted non-GAAP diluted EPS: $2.05
• Raised 2026 guidance: revenue $1,080–$1,140 million, adjusted EBITDA $285–$300 million, adjusted EPS $9.19–$9.69
• Cortrophin Gel 2026 net revenue guidance: $540–$575 million
• Share repurchase authorization: $100 million
• Share of revenue from Rare Disease: approximately 60% of total revenue (based on described performance)

What this might portend for ANIP and peers

The quarterly cadence matters here less for novelty and more for the credibility of ANIP’s multi-franchise portfolio. Cortrophin Gel’s 42.1% YoY revenue growth and its role as a centerpiece of the Rare Disease strategy suggest that the company’s mid-term trajectory hinges on converting clinical momentum into payer acceptance and broader clinician adoption. Weather-related physician office closures and insurance re-verifications, cited as seasonality drivers, are the kind of real-world headwinds that investors like to pretend don’t exist until they do. The company’s ability to moderate such manufacturing/distribution friction will be a key differentiator versus peers who rely on a single platform or indication.

Two numbers stand out beyond the headline revenue lift: first, the strong GAAP EPS and meaningful adjusted EPS imply that the core economics are holding up even as the portfolio expands. Second, the raised 2026 revenue forecast, with intact guidance for Cortrophin Gel’s net revenue and a substantial increase in the implied profitability metrics, points to an execution narrative—not just a revenue story. In practice, that means sector peers with similar Rare Disease or ophthalmology franchises might see a wedge open for market-share gains if their own sales forces scale effectively and if payer dynamics stay supportive.

Analysts’ EPS consensus and potential earnings surprises would be the next frontier. The filing itself does not publish consensus numbers, so any talk of an earnings surprise remains contingent on what street estimates were prior to the print. Still, the tone and the raised revenue forecast imply management expects more of the same—albeit with the usual caution about timing in insurance verification cycles and field-force ramp ramps. If ANIP sustains 2026 momentum, the stock could be priced as a more confidently diversified Rare Disease play with a healthy margin profile, alongside a growth-by-integration thesis in Generics.

Implications for peers and the sector

For peers, ANIP’s results are a reminder that a well-structured Rare Disease portfolio can be a durable revenue anchor, especially when complemented by a disciplined commercial expansion and a clear path to profitability. The emphasis on Cortrophin Gel’s growth, and the apparent success of the expanded sales force across neurology, rheumatology, nephrology, and ophthalmology, could spur competitive responses—whether through accelerated hiring, product line broadening, or strategic collaborations. The share repurchase authorization also signals a capital allocation stance that some investors may view as a vote of confidence, potentially influencing how peers balance buybacks with pipeline investment.

Forward-looking statements and what to watch

As with most earnings releases, the company frames forward-looking statements with risk factors. Investors should monitor: the pace of Cortrophin Gel adoption across target indications, payer contract dynamics, insurance verification timelines, and any shifts in the Rare Disease commercialization model. The 2026 revenue forecast and EPS ranges hinge on the durability of demand, the ability to scale the sales force, and the absorption of re-verification processes into normal operating rhythm. Sector peers will be watching whether ANIP’s performance translates into a durable premium for a diversified Rare Disease franchise or whether it simply reflects a temporarily favorable mix.

Bottom line

ANIP’s Q1 2026 results deliver a coherent narrative: solid topline growth, disciplined profitability, and a raised revenue forecast that underscores confidence in Cortrophin Gel and Rare Disease expansion. The absence of disclosed EPS consensus in the filing means investors still need to map the company’s reported metrics against external estimates, but the trajectory suggests that the ANIP story is less about one asset doing all the lifting and more about a portfolio that’s increasingly capable of delivering both revenue growth and earnings leverage. If the industry is a chorus, ANI appears to have added a few harmonies to the chorus—without sacrificing the tightness in its core rhythm.